An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Public ClinicalTrials.gov record NCT02854436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
Study identification
- NCT ID
- NCT02854436
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 289 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2016 (Actual)
- Primary completion
- Jan 26, 2021 (Actual)
- Completion
- Aug 16, 2023 (Actual)
- Last update posted
- Dec 22, 2025
2016 – 2023
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Evanston | Illinois | — | — |
| Not listed | Danville | Kentucky | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Lancaster | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02854436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 22, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02854436 live on ClinicalTrials.gov.